Sonnet Bio
@SonnetBio
Experts in immune-oncology therapies developing proprietary FHAB™ (Fully Human Albumin Binding) technology. (NASDAQ: $SONN)
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy bit.ly/4nHnlpb $SONN
Our deep knowledge of immune biology is complemented by our extensive drug discovery and development expertise. $SONN #Oncology #SolidTumors
At Sonnet BioTherapeutics, our primary mission is to pioneer the next generation of oncology-focused immune therapeutics for patients and clinicians. $SONN #Oncology #SolidTumors
#DidYouMissThis? $SONN leadership shared encouraging safety data for our lead program, SON-1010 (IL12-FHAB) — highlighting our progress and offering a look at what’s next in our mission to advance immune activation in oncology. Catch up here: vimeo.com/1075849028/ba2… #Oncology
Advancing Targeted Immune Activation to help turn ‘cold’ tumors ‘hot’—relentlessly working to unlock the immune system’s potential in difficult-to-treat cancers. $SONN #Oncology #SolidTumors
Our customizable platform was conceived to deliver cytokine payloads with demonstrated anti-tumor potential—designed to drive targeted immune responses for more effective therapies. Learn more: bit.ly/4c1CwT4 $SONN #Oncology #SolidTumors
⏳ Last chance to connect at #ASCO25! $SONN CEO Raghu Rao is in Chicago through June 3 for the ASCO Annual Meeting. 📩 Don’t miss the opportunity — reach out now to schedule a meeting: [email protected] #Oncology #SolidTumors
Headed to #ASCO25? So are we. $SONN CEO Raghu Rao will be in Chicago from May 30 – June 3 for the ASCO Annual Meeting. Want to connect? Reach out at [email protected] #Oncology #SolidTumors
Stay informed and receive company updates straight to your inbox. bit.ly/4cOlI3c $SONN #Oncology #Solid Tumors
Discover the science behind $SONN’s approach —leveraging our proprietary platform to develop a pipeline of single- and bi-functional therapies capable of stimulating and/or blocking immune-modulating targets. Learn more here: vimeo.com/1047192480/137… #Oncology #SolidTumors
Today is National Women’s Checkup Day—a reminder that your health deserves attention year-round. Regular checkups are an essential part of staying informed and proactive about your well-being. $SONN #Oncology #SolidTumors #NationalWomensCheckupDay #WomensCheckupDay
Today marks the start of National Women’s Health Week. We recognize the importance of accessible care, reliable information and empowering women to take charge of their health. Let’s continue to advocate for every woman’s well-being. $SONN #Oncology #SolidTumors #NWHW
Today is World Ovarian Cancer Day—a time to honor those affected, raise awareness and support the fight for better research and outcomes. Let’s get involved and make a difference. Learn more: bit.ly/3YUIUHZ $SONN #Oncology #SolidTumors #NHWM
6th Annual Cytokine-Based Drug Development Summit Boston, MA Dr. Kenney, CMO of $SONN, will present strategies to reduce toxicity and improve efficacy in: “Managing Toxicity Caused by the Overexpression of Cytokines to Widen the Therapeutic Window” Thursday, May 15 | 11:15 AM ET
May is #NationalWomensHealthMonth—a time to focus on the well-being of women. Let’s use this month to raise awareness about women’s health and encourage self-care and regular checkups. Learn more: bit.ly/3GO8sAn $SONN #Oncology #SolidTumors
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit bit.ly/4lRnYf7 $SONN #Oncology #SolidTumors
📩 Stay informed with Sonnet BioTherapeutics! Sign up for email alerts to receive the latest updates on our innovations, milestones and advancements in oncology. Subscribe now: bit.ly/4cOlI3c $SONN #Oncology #SolidTumors
At Sonnet BioTherapeutics, we are dedicated to improving immunotherapy response rates. bit.ly/3LAb18i $SONN #Oncology #SolidTumors
🚨#InCaseYouMissedIt: $SONN management shared positive safety results for SON-1010 in a #VirtualInvestor #WhatThisMeans segment, along with insights into what's next for the program. Catch up here: vimeo.com/1075849028/ba2… #SolidTumors #Oncology @InvestorVirtual
Our novel platform delivers either mono- or bifunctional immunomodulators and is linked to a Fully-Human, Albumin Binding scFv domain that provides enhanced targeting to the tumor microenvironment and prolonged retention in the tumor. $SONN #Oncology #SolidTumors
